Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 21, 2014; 20(15): 4316-4328
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4316
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4316
Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy
Kazuyuki Matsushita, Fumio Nomura, Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
Hideaki Shimada, Department of Surgery, School of Medicine, Toho University, Tokyo 143-8541, Japan
Yasuji Ueda, Makoto Inoue, Mamoru Hasegawa, DNAVEC Corporation, 6 Ohkubo, Tsukuba City, Ibaraki 300-2611, Japan
Takeshi Tomonaga, Proteome Research Center, Proteome Research Project, National Institute of Biomedical Innovation, Osaka 567-0085, Japan
Hisahiro Matsubara, Department of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan
Author contributions: Matsushita K designed the research; Matsushita K, Ueda Y and Inoue M performed the research; Shimada H, Tomonaga T, Hasegawa M, Matsubara H and Nomura F contributed new reagents/analytic tools and scientific discussions; Matsushita K analyzed the data and wrote the paper.
Supported by In part by the 21st Century COE (Center Of Excellence) Programs to Dr. Takenori Ochiai and by a Grant-in-Aid 18591453 to K.M from the Ministry of Education, Science, Sports and Culture of Japan
Correspondence to: Kazuyuki Matsushita, MD, PhD, Associate Professor, Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba 260-8670, Japan. kmatsu@faculty.chiba-u.jp
Telephone: +81-43-2227171 Fax: +81-43-2262169
Received: October 22, 2013
Revised: December 14, 2013
Accepted: January 19, 2014
Published online: April 21, 2014
Processing time: 176 Days and 14.5 Hours
Revised: December 14, 2013
Accepted: January 19, 2014
Published online: April 21, 2014
Processing time: 176 Days and 14.5 Hours
Core Tip
Core tip: The authors performed in vivo experiments and included an animal model to examine the Sendai virus/dF/Far Up Stream Element-Binding Protein-Interacting Repressor for cancer gene therapy to minimize side effects for clinical use.